{
    "hands_on_practices": [
        {
            "introduction": "The confidence interval (CI) method is a cornerstone of non-inferiority analysis. This approach assesses whether a new treatment is 'not unacceptably worse' by determining if the CI for the treatment difference lies on the acceptable side of a pre-defined non-inferiority margin, $\\Delta$. This practice provides a direct application of this core principle, challenging you to perform the fundamental calculation for assessing non-inferiority. ",
            "id": "4591103",
            "problem": "A non-inferiority trial compares a new antibiotic to an established active control, assessing the incidence rate of a specific adverse event. Let $d$ denote the incidence rate difference defined as $d = \\text{rate}_{\\text{new}} - \\text{rate}_{\\text{control}}$, measured in events per $1000$ person-years. The non-inferiority margin is $\\Delta = 1.0$, meaning the new antibiotic is considered non-inferior if the excess adverse event rate does not exceed $1.0$ event per $1000$ person-years. The point estimate of the rate difference is $\\hat{d} = 0.8$ with standard error $\\mathrm{SE}(\\hat{d}) = 0.5$. The significance level for a one-sided assessment is $\\alpha = 0.025$.\n\nUsing the Confidence Interval (CI) criterion under the large-sample normal approximation, compute the one-sided $(1-\\alpha)$ upper confidence limit for $d$. Round your answer to four significant figures. Express your final numeric answer in events per $1000$ person-years. Provide only the numeric value of this upper limit as your final answer.",
            "solution": "The objective is to compute the one-sided $(1-\\alpha)$ upper confidence limit (UCL) for the incidence rate difference, $d$. The calculation is based on the large-sample normal approximation.\n\nThe formula for a one-sided $(1-\\alpha)$ upper confidence limit is:\n$$ \\text{UCL}_{1-\\alpha}(d) = \\hat{d} + z_{1-\\alpha} \\cdot \\mathrm{SE}(\\hat{d}) $$\nwhere $\\hat{d}$ is the point estimate, $\\mathrm{SE}(\\hat{d})$ is its standard error, and $z_{1-\\alpha}$ is the critical value from the standard normal distribution.\n\nThe problem provides the following values:\n- Point estimate: $\\hat{d} = 0.8$\n- Standard error: $\\mathrm{SE}(\\hat{d}) = 0.5$\n- One-sided significance level: $\\alpha = 0.025$\n\nFirst, we find the critical value $z_{1-\\alpha}$.\nThe confidence level is $1-\\alpha = 1 - 0.025 = 0.975$.\nThe critical value $z_{0.975}$ is the value for which the cumulative probability in a standard normal distribution is $0.975$. This value is approximately $1.96$.\n\nNext, we substitute the values into the formula:\n$$ \\text{UCL}_{0.975}(d) = 0.8 + 1.96 \\times 0.5 $$\n$$ \\text{UCL}_{0.975}(d) = 0.8 + 0.98 = 1.78 $$\n\nThe problem requires the answer to be rounded to four significant figures. The value $1.78$ has three significant figures. To express it with four, we add a trailing zero: $1.780$.\nThe final answer is the numeric value of this upper limit.",
            "answer": "$$\\boxed{1.780}$$"
        },
        {
            "introduction": "A common pitfall in interpreting clinical trial results is assuming that a failure to demonstrate superiority implies that two treatments are equivalent. This is not the case, as a trial might simply lack the statistical power to draw either conclusion, resulting in an 'inconclusive' finding. This exercise challenges you to navigate this ambiguity by using confidence intervals to correctly distinguish between the distinct outcomes of superiority, equivalence, and an inconclusive result. ",
            "id": "4951263",
            "problem": "A randomized, double-blind trial compares a new antihypertensive agent to standard therapy on the binary endpoint of treatment response. Let the risk difference be defined as $\\Delta = p_{\\text{new}} - p_{\\text{standard}}$, where larger $\\Delta$ indicates a higher response rate with the new agent. Investigators prespecified an equivalence margin $\\delta = 0.10$ (ten percentage points). At significance level $\\alpha = 0.05$, they performed a superiority analysis and also assessed equivalence using the Two One-Sided Tests (TOST) framework. The estimated difference produced a 95% confidence interval $[-0.14, 0.18]$ and a 90% confidence interval $[-0.12, 0.16]$. The superiority analysis did not achieve statistical significance at $\\alpha = 0.05$.\n\nWhich option best explains, using the formal hypothesis relationships for TOST with $\\delta$, why failure to demonstrate superiority does not imply equivalence, and correctly interprets the numeric confidence intervals?\n\nA. Superiority tests $H_{0}: \\Delta \\le 0$ versus $H_{1}: \\Delta  0$. Equivalence via TOST tests $H_{0}: \\Delta \\le -\\delta$ or $\\Delta \\ge \\delta$ versus $H_{1}: -\\delta  \\Delta  \\delta$. With $\\delta = 0.10$, the 90% confidence interval $[-0.12, 0.16]$ is not fully contained in $(-0.10, 0.10)$, so equivalence is not established even though superiority was not demonstrated.\n\nB. If the 95% confidence interval includes $0$, the treatments are equivalent, so failure to demonstrate superiority immediately implies equivalence.\n\nC. Equivalence is demonstrated whenever the 95% confidence interval lies within $(-\\delta, \\delta)$, so the absence of superiority is sufficient for equivalence if the interval is wide enough.\n\nD. Failure to show superiority implies non-inferiority, and non-inferiority is the same as equivalence; therefore not rejecting $H_{0}: \\Delta \\le 0$ means $- \\delta  \\Delta  \\delta$ holds.",
            "solution": "The problem requires interpreting confidence intervals to distinguish between the outcomes of a superiority test and an equivalence test.\n\n**1. Define the Hypotheses and Test Procedures**\n\n*   **Superiority Test:** Aims to prove the new agent is better. The hypotheses are $H_{0, \\text{sup}}: \\Delta \\le 0$ versus $H_{1, \\text{sup}}: \\Delta > 0$. Failure to show superiority means we fail to reject $H_{0, \\text{sup}}$.\n*   **Equivalence Test (TOST):** Aims to prove the new agent is clinically similar to the standard, i.e., $-\\delta  \\Delta  \\delta$. The null hypothesis is that they are not equivalent: $H_{0, \\text{eq}}: \\Delta \\le -\\delta \\text{ or } \\Delta \\ge \\delta$.\n\n**2. Link to Confidence Intervals**\n\nThe Two One-Sided Tests (TOST) procedure at significance level $\\alpha$ is equivalent to checking if the $(1-2\\alpha)$ confidence interval for $\\Delta$ is entirely contained within the equivalence margin $(-\\delta, \\delta)$.\n- Given $\\alpha = 0.05$, the required confidence interval is the $(1 - 2 \\times 0.05) = 90\\%$ CI.\n- The equivalence margin is $\\delta = 0.10$, so the equivalence region is $(-0.10, 0.10)$.\n\n**3. Apply to the Data**\n\n- The provided 90% CI for $\\Delta$ is $[-0.12, 0.16]$.\n- To check for equivalence, we compare this CI to the region $(-0.10, 0.10)$.\n  - The lower bound of the CI, $-0.12$, is *not* greater than $-0.10$.\n  - The upper bound of the CI, $0.16$, is *not* less than $0.10$.\n- Since the 90% CI is not fully contained within $(-0.10, 0.10)$, we fail to reject $H_{0, \\text{eq}}$. Equivalence is **not** established.\n\nThe problem states superiority was not demonstrated. This is consistent with the CI, as the lower bound of the 90% CI ($-0.12$) is not greater than $0$.\nThe study is therefore inconclusive: it failed to show superiority and also failed to show equivalence. This happens because the CI is too wide, reflecting insufficient precision.\n\n**4. Evaluate the Options**\n\n*   **A:** Correctly states the hypotheses for superiority and equivalence, correctly uses the 90% CI for TOST at $\\alpha=0.05$, and correctly concludes that equivalence is not established because the CI $[-0.12, 0.16]$ is not contained within $(-0.10, 0.10)$. This option accurately describes the situation.\n*   **B:** Incorrectly equates \"CI includes 0\" with equivalence.\n*   **C:** Incorrectly refers to the 95% CI for the TOST procedure and incorrectly suggests a wide interval helps establish equivalence.\n*   **D:** Makes several false claims about the relationship between superiority, non-inferiority, and equivalence.\n\nThus, option A provides the correct explanation.",
            "answer": "$$\\boxed{A}$$"
        },
        {
            "introduction": "Real-world clinical trials must contend with patient non-adherence, where participants do not follow their assigned treatment protocol. This complication requires careful consideration of different analysis populations, namely the intention-to-treat (ITT) and per-protocol (PP) groups. This final practice explores how non-adherence can dilute treatment effects and paradoxically make it easier to claim non-inferiority, highlighting why regulators often require robust evidence from both analysis sets. ",
            "id": "4591169",
            "problem": "A two-arm randomized non-inferiority trial compares a new oral antibiotic to standard therapy for community-acquired pneumonia. The primary endpoint is clinical cure by day $14$. The non-inferiority margin is specified on the risk difference scale as $M=-0.10$ (new minus standard). Randomization assigns $n=500$ participants to each arm. Suppose the following hold:\n\n- Among participants who adhere to their assigned therapy (receive the assigned treatment for a full course), the cure probabilities are $p_{\\text{new,adher}}=0.80$ and $p_{\\text{std,adher}}=0.89$.\n- There is symmetric all-or-none cross-over: in each randomized arm, 20% do not adhere and instead receive the other armâ€™s therapy, while 80% adhere. Assume that non-adherence does not change the underlying efficacy of the therapy actually received.\n\nUse the intention-to-treat (ITT) principle (analyze by randomized arm) and the per-protocol (PP) principle (restrict to adherers) to address the following. Work from first principles: define the group-level cure risks under ITT as the appropriate mixture of cure risks among adherers and non-adherers, and define the PP cure risks as the adherer risks. Use large-sample Wald approximations for $95\\%$ confidence intervals for the risk difference, with standard error $\\sqrt{p_1(1-p_1)/n_1+p_0(1-p_0)/n_0}$ for arms $1$ and $0$, ignoring finite-sample and continuity corrections.\n\nWhich statement best characterizes whether ITT dilutes differences toward zero and whether this favors non-inferiority conclusions relative to PP in this scenario?\n\nA. Under symmetric 20% cross-over, the ITT estimate is diluted toward $0$ compared with the PP effect; with $n=500$ per arm and $M=-0.10$, the ITT $95\\%$ confidence interval lies entirely above $-0.10$ while the PP $95\\%$ confidence interval does not, so ITT favors concluding non-inferiority relative to PP.\n\nB. Under symmetric 20% cross-over, the ITT estimate exaggerates differences away from $0$ and is less likely than PP to conclude non-inferiority.\n\nC. With 20% non-adherence in both arms, ITT and PP produce identical risk differences and confidence intervals, so non-inferiority conclusions are unaffected.\n\nD. Because non-inferiority trials must always prefer ITT for conservatism, the ITT analysis is the only valid basis for concluding non-inferiority even if PP fails.",
            "solution": "The analysis requires calculating the risk difference and its $95\\%$ confidence interval under both the Per-Protocol (PP) and Intention-to-Treat (ITT) principles. A conclusion of non-inferiority is established if the lower bound of the $95\\%$ CI for the risk difference (new minus standard) is greater than the non-inferiority margin, $M = -0.10$.\n\n**1. Per-Protocol (PP) Analysis**\n\nThe PP analysis is restricted to participants who adhered to their assigned therapy.\n\n- The proportion of adherers in each arm is $80\\%$. The sample size for the PP analysis in the new arm is $n_{\\text{new,PP}} = 0.80 \\times 500 = 400$. Similarly, $n_{\\text{std,PP}} = 400$.\n- The cure probabilities for the PP populations are given as the adherer probabilities:\n  - $p_{\\text{new,PP}} = p_{\\text{new,adher}} = 0.80$\n  - $p_{\\text{std,PP}} = p_{\\text{std,adher}} = 0.89$\n- The PP risk difference is:\n  $$ \\Delta_{\\text{PP}} = p_{\\text{new,PP}} - p_{\\text{std,PP}} = 0.80 - 0.89 = -0.09 $$\n- The standard error of the PP risk difference is:\n  $$ SE(\\Delta_{\\text{PP}}) = \\sqrt{\\frac{p_{\\text{new,PP}}(1-p_{\\text{new,PP}})}{n_{\\text{new,PP}}} + \\frac{p_{\\text{std,PP}}(1-p_{\\text{std,PP}})}{n_{\\text{std,PP}}}} $$\n  $$ SE(\\Delta_{\\text{PP}}) = \\sqrt{\\frac{0.80(1-0.80)}{400} + \\frac{0.89(1-0.89)}{400}} $$\n  $$ SE(\\Delta_{\\text{PP}}) = \\sqrt{\\frac{0.16}{400} + \\frac{0.0979}{400}} = \\sqrt{\\frac{0.2579}{400}} \\approx \\sqrt{0.00064475} \\approx 0.02539 $$\n- The $95\\%$ Wald CI for the PP risk difference is $\\Delta_{\\text{PP}} \\pm 1.96 \\times SE(\\Delta_{\\text{PP}})$:\n  $$ CI_{\\text{PP}} = -0.09 \\pm 1.96 \\times 0.02539 = -0.09 \\pm 0.04976 $$\n  $$ CI_{\\text{PP}} = [-0.13976, -0.04024] $$\n- **Conclusion for PP:** The lower bound of the CI, $-0.13976$, is less than the non-inferiority margin $M = -0.10$. Therefore, the PP analysis fails to demonstrate non-inferiority.\n\n**2. Intention-to-Treat (ITT) Analysis**\n\nThe ITT analysis includes all $n=500$ participants in each arm as randomized. The observed cure probability in each arm is a mixture of outcomes from adherers and non-adherers (who cross over).\n\n- The sample sizes are $n_{\\text{new,ITT}} = 500$ and $n_{\\text{std,ITT}} = 500$.\n- **Cure probability in the arm randomized to the new therapy ($p_{\\text{new,ITT}}$):**\n  - $80\\%$ of this group adhere and receive the new therapy (cure probability $p_{\\text{new,adher}} = 0.80$).\n  - $20\\%$ of this group cross over and receive the standard therapy (cure probability $p_{\\text{std,adher}} = 0.89$).\n  - $p_{\\text{new,ITT}} = (0.80 \\times p_{\\text{new,adher}}) + (0.20 \\times p_{\\text{std,adher}}) = (0.80 \\times 0.80) + (0.20 \\times 0.89) = 0.64 + 0.178 = 0.818$.\n- **Cure probability in the arm randomized to the standard therapy ($p_{\\text{std,ITT}}$):**\n  - $80\\%$ of this group adhere and receive the standard therapy (cure probability $p_{\\text{std,adher}} = 0.89$).\n  - $20\\%$ of this group cross over and receive the new therapy (cure probability $p_{\\text{new,adher}} = 0.80$).\n  - $p_{\\text{std,ITT}} = (0.80 \\times p_{\\text{std,adher}}) + (0.20 \\times p_{\\text{new,adher}}) = (0.80 \\times 0.89) + (0.20 \\times 0.80) = 0.712 + 0.160 = 0.872$.\n- The ITT risk difference is:\n  $$ \\Delta_{\\text{ITT}} = p_{\\text{new,ITT}} - p_{\\text{std,ITT}} = 0.818 - 0.872 = -0.054 $$\n- The standard error of the ITT risk difference is:\n  $$ SE(\\Delta_{\\text{ITT}}) = \\sqrt{\\frac{p_{\\text{new,ITT}}(1-p_{\\text{new,ITT}})}{n_{\\text{new,ITT}}} + \\frac{p_{\\text{std,ITT}}(1-p_{\\text{std,ITT}})}{n_{\\text{std,ITT}}}} $$\n  $$ SE(\\Delta_{\\text{ITT}}) = \\sqrt{\\frac{0.818(1-0.818)}{500} + \\frac{0.872(1-0.872)}{500}} $$\n  $$ SE(\\Delta_{\\text{ITT}}) = \\sqrt{\\frac{0.148876}{500} + \\frac{0.111616}{500}} = \\sqrt{\\frac{0.260492}{500}} \\approx \\sqrt{0.00052098} \\approx 0.02283 $$\n- The $95\\%$ Wald CI for the ITT risk difference is $\\Delta_{\\text{ITT}} \\pm 1.96 \\times SE(\\Delta_{\\text{ITT}})$:\n  $$ CI_{\\text{ITT}} = -0.054 \\pm 1.96 \\times 0.02283 = -0.054 \\pm 0.04475 $$\n  $$ CI_{\\text{ITT}} = [-0.09875, -0.00925] $$\n- **Conclusion for ITT:** The lower bound of the CI, $-0.09875$, is greater than the non-inferiority margin $M = -0.10$. Therefore, the ITT analysis demonstrates non-inferiority.\n\n**3. Comparison and Option Evaluation**\n\n- **Dilution Effect:** The PP risk difference is $\\Delta_{\\text{PP}} = -0.09$. The ITT risk difference is $\\Delta_{\\text{ITT}} = -0.054$. Since $|\\Delta_{\\text{ITT}}|  |\\Delta_{\\text{PP}}|$, the symmetric cross-over has diluted the observed effect estimate towards the null value of $0$.\n- **Effect on Conclusion:** The PP analysis failed to show non-inferiority, while the ITT analysis succeeded. In this scenario, using the ITT principle favors the conclusion of non-inferiority compared to using the PP principle.\n\n**Option-by-Option Analysis**\n\n**A. Under symmetric 20% cross-over, the ITT estimate is diluted toward $0$ compared with the PP effect; with $n=500$ per arm and $M=-0.10$, the ITT $95\\%$ confidence interval lies entirely above $-0.10$ while the PP $95\\%$ confidence interval does not, so ITT favors concluding non-inferiority relative to PP.**\n- This statement accurately summarizes the derived results. The ITT estimate ($-0.054$) is indeed diluted toward $0$ compared to the PP estimate ($-0.09$). The ITT CI lower bound ($-0.09875$) is above $-0.10$, while the PP CI lower bound ($-0.13976$) is not. Consequently, the ITT analysis leads to a non-inferiority conclusion where the PP analysis does not.\n- **Verdict: Correct.**\n\n**B. Under symmetric 20% cross-over, the ITT estimate exaggerates differences away from $0$ and is less likely than PP to conclude non-inferiority.**\n- The ITT estimate of the difference, $\\Delta_{\\text{ITT}}=-0.054$, is smaller in magnitude than the PP estimate, $\\Delta_{\\text{PP}}=-0.09$. Thus, it represents a dilution toward $0$, not an exaggeration. In this specific case, it was more likely, not less likely, to conclude non-inferiority.\n- **Verdict: Incorrect.**\n\n**C. With 20% non-adherence in both arms, ITT and PP produce identical risk differences and confidence intervals, so non-inferiority conclusions are unaffected.**\n- The calculations clearly show that the risk differences ($\\Delta_{\\text{ITT}} = -0.054$ vs. $\\Delta_{\\text{PP}} = -0.09$) and the confidence intervals ($CI_{\\text{ITT}} \\approx [-0.099, -0.009]$ vs. $CI_{\\text{PP}} \\approx [-0.140, -0.040]$) are not identical.\n- **Verdict: Incorrect.**\n\n**D. Because non-inferiority trials must always prefer ITT for conservatism, the ITT analysis is the only valid basis for concluding non-inferiority even if PP fails.**\n- This statement contains a critical flaw in reasoning. In superiority trials, ITT is generally conservative because dilution biases the effect toward the null, making it harder to show a difference. However, in non-inferiority trials, this same dilution toward the null can be *anti-conservative*, making it easier to claim that a new, inferior treatment is non-inferior (as demonstrated in this problem). For this reason, regulatory bodies often require that non-inferiority be demonstrated in both the ITT and PP populations to ensure a robust conclusion. The premise that ITT is \"always\" preferred for \"conservatism\" in non-inferiority trials is false.\n- **Verdict: Incorrect.**",
            "answer": "$$\\boxed{A}$$"
        }
    ]
}